{"id":"galvus-vildagliptin","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hypoglycemia (when combined with other agents)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking DPP-4 enzyme activity, vildagliptin prevents the degradation of GLP-1 and GIP, two incretin hormones that enhance glucose-dependent insulin secretion from pancreatic beta cells. This mechanism lowers blood glucose levels in a glucose-dependent manner, reducing hypoglycemia risk. The drug is effective as monotherapy or in combination with other antidiabetic agents.","oneSentence":"Vildagliptin inhibits dipeptidyl peptidase-4 (DPP-4), allowing incretin hormones to accumulate and stimulate insulin secretion in response to glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:55.967Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02176681","phase":"PHASE4","title":"A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2014-06","conditions":"Haemodialyzed, Type 2 Diabetes","enrollment":70},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT06142656","phase":"PHASE2, PHASE3","title":"Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome","status":"RECRUITING","sponsor":"October 6 University","startDate":"2023-11-25","conditions":"Poly Cystic Ovary Syndrome","enrollment":60},{"nctId":"NCT04300790","phase":"PHASE2","title":"Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-23","conditions":"Breast Cancer","enrollment":69},{"nctId":"NCT07077525","phase":"PHASE4","title":"Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2023-06-01","conditions":"Type 2 Diabetes","enrollment":196},{"nctId":"NCT04761861","phase":"PHASE2","title":"Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2021-02-16","conditions":"Schizophrenia, Dyslipidemias","enrollment":""},{"nctId":"NCT04410341","phase":"PHASE1, PHASE2","title":"The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2020-05-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT03492580","phase":"","title":"A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-22","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":714582},{"nctId":"NCT04841096","phase":"PHASE3","title":"Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2023-03-21","conditions":"Type 2 Diabetes","enrollment":162},{"nctId":"NCT01242228","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-21","conditions":"Type 2 Diabetes Mellitus","enrollment":106},{"nctId":"NCT06951334","phase":"NA","title":"Clinical Trial of Vildagliptin in Early Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2025-06-01","conditions":"Parkinson's Disease","enrollment":66},{"nctId":"NCT06913101","phase":"NA","title":"Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"PNS Hafeez - Naval Hospital","startDate":"2024-11-15","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":102},{"nctId":"NCT06889909","phase":"NA","title":"Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lahore General Hospital","startDate":"2024-12-15","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":102},{"nctId":"NCT06068686","phase":"NA","title":"Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2022-10-01","conditions":"Type 2 Diabetes","enrollment":70},{"nctId":"NCT06313008","phase":"NA","title":"Empagliflozin Versus Vildagliptin in CAD Patients With T2DM","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2023-08-10","conditions":"Coronary Artery Disease, Type 2 Diabetes","enrollment":120},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT03939624","phase":"","title":"Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Type2 Diabetes, Myocardial Infarction, Ischemic Stroke","enrollment":419734},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT03918148","phase":"","title":"Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2018-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":1150},{"nctId":"NCT06248801","phase":"PHASE1","title":"Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets","status":"UNKNOWN","sponsor":"Bio-innova Co., Ltd","startDate":"2024-09-05","conditions":"Healthy Subjects","enrollment":48},{"nctId":"NCT06244407","phase":"PHASE1","title":"The Bioequivalence Study of Fixed-dose Combination of Vildagliptin and Metformin HCI 50/1000 mg FCT Under Fed Conditions","status":"UNKNOWN","sponsor":"International Bio service","startDate":"2024-05-23","conditions":"Healthy Volunteer","enrollment":40},{"nctId":"NCT03014479","phase":"PHASE4","title":"Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-18","conditions":"Type 2 Diabetes","enrollment":219},{"nctId":"NCT05369793","phase":"PHASE3","title":"Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-08-01","conditions":"Type 2 Diabetes (Adult Onset), Diabetic Neuropathies","enrollment":60},{"nctId":"NCT05366868","phase":"PHASE4","title":"Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2022-05-26","conditions":"Diabetes Mellitus, Type 2","enrollment":567},{"nctId":"NCT06103747","phase":"PHASE1","title":"Bioequivalence Study to Compare Metformin / Vildagliptin (850 mg/50 mg) Versus Galvumet®","status":"COMPLETED","sponsor":"Reseach Laboratory of Clinical and Experimental Pharmacology","startDate":"2023-02-21","conditions":"Fed Conditions","enrollment":18},{"nctId":"NCT06073600","phase":"PHASE1","title":"Bioequivalence Study to Compare Metformin / Vildagliptin Versus Galvumet®","status":"COMPLETED","sponsor":"Reseach Laboratory of Clinical and Experimental Pharmacology","startDate":"2022-05-20","conditions":"Fed Conditions","enrollment":18},{"nctId":"NCT06010992","phase":"PHASE2","title":"Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-10-01","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT05902468","phase":"PHASE2, PHASE3","title":"Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-06-28","conditions":"Diabetes Mellitus, Type 2","enrollment":88},{"nctId":"NCT03693560","phase":"PHASE4","title":"Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2018-10-08","conditions":"Coronary Artery Disease, Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT02849899","phase":"PHASE3","title":"Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2018-10-26","conditions":"Disorder Related to Renal Transplantation, Diabetes","enrollment":186},{"nctId":"NCT05347459","phase":"","title":"Cognitive Protective Effect of Newer Antidiabetic Drugs","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-03-02","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT05429554","phase":"","title":"The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"MTI University","startDate":"2022-06","conditions":"Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT05359432","phase":"PHASE4","title":"Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2020-07-01","conditions":"Type 2 Diabetes","enrollment":120},{"nctId":"NCT05337969","phase":"NA","title":"The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Assessed.","status":"COMPLETED","sponsor":"AET Laboratories Private Limited","startDate":"2015-12","conditions":"To Determine Bioequivalence Under Fed Conditions","enrollment":60},{"nctId":"NCT05329844","phase":"NA","title":"The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.","status":"COMPLETED","sponsor":"AET Laboratories Private Limited","startDate":"2014-02","conditions":"Diabetes Mellitus","enrollment":66},{"nctId":"NCT05329857","phase":"NA","title":"The Study Intends to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Evaluated.","status":"COMPLETED","sponsor":"AET Laboratories Private Limited","startDate":"2015-12","conditions":"To Determine Bioequivalence Under Fed Conditions","enrollment":60},{"nctId":"NCT03958591","phase":"PHASE4","title":"Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification","status":"UNKNOWN","sponsor":"Yanbing Li","startDate":"2019-05-01","conditions":"Diabetes type2","enrollment":274},{"nctId":"NCT05102149","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"PegBio Co., Ltd.","startDate":"2021-09-30","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":672},{"nctId":"NCT05041673","phase":"NA","title":"Anti-diabetic Drugs and Fatty Liver Management","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2021-02-23","conditions":"Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2","enrollment":120},{"nctId":"NCT02862470","phase":"","title":"Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2016-08-05","conditions":"Thyroid Cancer","enrollment":22},{"nctId":"NCT04916093","phase":"PHASE4","title":"Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2019-12-20","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT00860288","phase":"PHASE2, PHASE3","title":"Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1988},{"nctId":"NCT00382096","phase":"PHASE3","title":"Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":"Diabetes Mellitus, Type 2","enrollment":1179},{"nctId":"NCT04654676","phase":"PHASE4","title":"DPP4 Inhibitor on Glycemic Variability","status":"COMPLETED","sponsor":"University Malaysia Sarawak","startDate":"2018-09-15","conditions":"Diabetes Mellitus, Type 2","enrollment":12},{"nctId":"NCT00728351","phase":"PHASE3","title":"Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-06","conditions":"Diabetes Mellitus, Type 2","enrollment":317},{"nctId":"NCT01309698","phase":"PHASE4","title":"Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-02","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT00468039","phase":"PHASE3","title":"A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-03-06","conditions":"Diabetes Mellitus, Type 2","enrollment":94},{"nctId":"NCT00821977","phase":"PHASE2, PHASE3","title":"Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-11","conditions":"Diabetes Mellitus, Type 2","enrollment":338},{"nctId":"NCT00383578","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-09","conditions":"Diabetes Mellitus, Type 2","enrollment":335},{"nctId":"NCT00396357","phase":"PHASE3","title":"Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 2","enrollment":914},{"nctId":"NCT00765830","phase":"PHASE3","title":"Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":"Diabetes Mellitus, Type 2, Renal Insufficiency","enrollment":349},{"nctId":"NCT00616811","phase":"PHASE3","title":"Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-01","conditions":"Diabetes Mellitus, Type 2","enrollment":148},{"nctId":"NCT00099853","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-05","conditions":"Diabetes Mellitus, Type 2","enrollment":362},{"nctId":"NCT00106340","phase":"PHASE3","title":"Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":3118},{"nctId":"NCT00770081","phase":"PHASE3","title":"Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":"Diabetes Mellitus, Type 2, Renal Insufficiency","enrollment":75},{"nctId":"NCT00646542","phase":"PHASE3","title":"Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":525},{"nctId":"NCT00260156","phase":"PHASE3","title":"A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-11","conditions":"Diabetes Mellitus, Type 2","enrollment":59},{"nctId":"NCT00818571","phase":"PHASE1, PHASE2","title":"Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-12","conditions":"Renal Impairment, Diabetes","enrollment":96},{"nctId":"NCT00102466","phase":"PHASE3","title":"Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1007},{"nctId":"NCT00894868","phase":"PHASE4","title":"Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-05","conditions":"Congestive Heart Failure, Type II Diabetes Mellitus","enrollment":798},{"nctId":"NCT01159249","phase":"PHASE3","title":"Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":245},{"nctId":"NCT00633997","phase":"PHASE1, PHASE2","title":"Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Novartis","startDate":"2008-02","conditions":"Diabetes Mellitus, Type 2","enrollment":22},{"nctId":"NCT02803892","phase":"PHASE2","title":"Monotherapy With Rapamycin in Long-standing Type 1 Diabetes","status":"COMPLETED","sponsor":"Piemonti Lorenzo","startDate":"2016-05","conditions":"Diabetes Mellitus, Type 1","enrollment":55},{"nctId":"NCT01528254","phase":"PHASE4","title":"VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03-30","conditions":"Type 2 Diabetes Mellitus","enrollment":2004},{"nctId":"NCT00936234","phase":"PHASE2, PHASE3","title":"Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).","status":"WITHDRAWN","sponsor":"Johann Wolfgang Goethe University Hospital","startDate":"2009-07","conditions":"SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors","enrollment":""},{"nctId":"NCT04485845","phase":"PHASE4","title":"Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2019-11-01","conditions":"Metabolic Syndrome, Diabete Type 2, Kidney Insufficiency","enrollment":39},{"nctId":"NCT00390520","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-09","conditions":"Diabetes Mellitus, Type 2","enrollment":28},{"nctId":"NCT04237493","phase":"PHASE4","title":"Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan","status":"COMPLETED","sponsor":"University of Jordan","startDate":"2017-02-14","conditions":"Diabetes Mellitus, Type 2","enrollment":687},{"nctId":"NCT03804411","phase":"PHASE4","title":"Prognostic Predictors of Response to Hypoglycemic Therapy","status":"UNKNOWN","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2017-08-01","conditions":"Diabetes Mellitus, Type 2","enrollment":800},{"nctId":"NCT03577184","phase":"","title":"Evaluating the Glycemic Control wIth Vildagliptin and Metformin Combination Therapy.","status":"WITHDRAWN","sponsor":"Clinision","startDate":"2018-07","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT04087525","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety of HIP1701 in Healthy Subjects","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-10-23","conditions":"Health, Subjective","enrollment":31},{"nctId":"NCT04081857","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety of HCP1704 in Healthy Subjects","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-06-03","conditions":"Health, Subjective","enrollment":48},{"nctId":"NCT03983551","phase":"PHASE4","title":"Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas","status":"COMPLETED","sponsor":"Changhua Christian Hospital","startDate":"2016-03-01","conditions":"Type 2 Diabetes Mellitus, Proteinuria","enrollment":101},{"nctId":"NCT01862263","phase":"PHASE4","title":"Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-05","conditions":"Type 2 Diabetes Mellitus","enrollment":191},{"nctId":"NCT02475070","phase":"PHASE4","title":"Vildagliptin Versus Dapagliflozin on Glucagon","status":"COMPLETED","sponsor":"Lund University","startDate":"2016-01","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT03925701","phase":"PHASE3","title":"Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2019-04-01","conditions":"dm","enrollment":120},{"nctId":"NCT02853630","phase":"PHASE4","title":"A Clinical Trial to Study the Effects of Two Drugs, Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals","startDate":"2013-12","conditions":"TYpe 2 Diabetes Mellitus","enrollment":203},{"nctId":"NCT01882907","phase":"PHASE4","title":"Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Pusan National University Hospital","startDate":"2009-12","conditions":"Type 2 Diabetes","enrollment":287},{"nctId":"NCT03819127","phase":"PHASE4","title":"Vildagliptin in Older Adults With Diabetes and Mild Cognitive Impairment","status":"COMPLETED","sponsor":"University of Catania","startDate":"2015-01","conditions":"Mild Cognitive Impairment","enrollment":60},{"nctId":"NCT01404676","phase":"PHASE4","title":"The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-06","conditions":"Type 2 Diabetes Mellitus","enrollment":34},{"nctId":"NCT03178591","phase":"PHASE4","title":"Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2014-10","conditions":"Diabetes Mellitus, Type 2, Ischemic Heart Disease","enrollment":43},{"nctId":"NCT03563794","phase":"PHASE4","title":"Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2018-06-10","conditions":"T2DM","enrollment":400},{"nctId":"NCT03500900","phase":"NA","title":"Vildagliptin on Gastric Accommodation","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-03-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT02312427","phase":"PHASE4","title":"DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure","status":"COMPLETED","sponsor":"Mitsui Memorial Hospital","startDate":"2015-01","conditions":"Heart Failure, Diabetes Mellitus","enrollment":10},{"nctId":"NCT02832999","phase":"PHASE4","title":"Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes","status":"COMPLETED","sponsor":"Yaounde Central Hospital","startDate":"2016-01","conditions":"Type 2 Diabetes Mellitus","enrollment":14},{"nctId":"NCT02089438","phase":"PHASE4","title":"DPP-4 Inhibition, Incretins and Islet Function","status":"COMPLETED","sponsor":"Lund University","startDate":"2014-05","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT03253562","phase":"PHASE4","title":"Metformin Versus Vildagliptin for Diabetic Hypertensive Patients","status":"COMPLETED","sponsor":"MTI University","startDate":"2017-02-01","conditions":"Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients","enrollment":120},{"nctId":"NCT00099892","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-05","conditions":"Diabetes Mellitus, Type 2","enrollment":544},{"nctId":"NCT00300287","phase":"PHASE3","title":"A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-02-20","conditions":"Diabetes Mellitus, Type 2","enrollment":150},{"nctId":"NCT01822548","phase":"PHASE3","title":"Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria di Parma","startDate":"2010-10","conditions":"Type 2 Diabetes","enrollment":64},{"nctId":"NCT01196546","phase":"PHASE4","title":"Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-03","conditions":"Type 2 Diabetes Mellitus","enrollment":161},{"nctId":"NCT02007278","phase":"PHASE4","title":"Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-01-03","conditions":"Type 2 Diabetes, Hypoglycemia","enrollment":40},{"nctId":"NCT01827280","phase":"PHASE4","title":"Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women","status":"COMPLETED","sponsor":"Rio de Janeiro State University","startDate":"2013-04","conditions":"1- Microvascular Function, 2-oxidative Stress, 3-inflammation","enrollment":40},{"nctId":"NCT01582308","phase":"PHASE1","title":"A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-06-21","conditions":"Type 2 Diabetes Mellitus","enrollment":22},{"nctId":"NCT00120536","phase":"PHASE3","title":"Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-06","conditions":"Diabetes Mellitus, Type 2","enrollment":288},{"nctId":"NCT00099918","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-05","conditions":"Diabetes Mellitus, Type 2","enrollment":717},{"nctId":"NCT00101803","phase":"PHASE3","title":"Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-01","conditions":"Diabetes Mellitus, Type 2","enrollment":527},{"nctId":"NCT01766778","phase":"PHASE4","title":"Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-05-13","conditions":"Type-2 Diabetes Mellitus","enrollment":117}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":2,"reaction":"CHEST PAIN"},{"count":2,"reaction":"DUODENAL ULCER HAEMORRHAGE"},{"count":2,"reaction":"HYPOGLYCAEMIA"},{"count":2,"reaction":"MYOCARDIAL INFARCTION"},{"count":2,"reaction":"VOMITING"},{"count":1,"reaction":"ANGINA PECTORIS"},{"count":1,"reaction":"ARRHYTHMIA"},{"count":1,"reaction":"BLISTER"},{"count":1,"reaction":"BLOOD GLUCOSE INCREASED"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Galvus (vildagliptin)","genericName":"Galvus (vildagliptin)","companyName":"Korea University Anam Hospital","companyId":"korea-university-anam-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vildagliptin inhibits dipeptidyl peptidase-4 (DPP-4), allowing incretin hormones to accumulate and stimulate insulin secretion in response to glucose. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}